[A21-45] Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97
Last updated 20.05.2021
Project no.:
A21-45
Commission:
Commission awarded on 07.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy
unchanged after addendum:
Patients with Child-Pugh A or no liver cirrhosis
- with viral aetiology of HCC: indication of major added benefit,
- with non-viral aetiology of HCC: hint of considerable added benefit.
Patients with Child-Pugh B: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-97 | Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-05-20: A G-BA decision was published